Exposure to biomass fuel is large contributor of COPD in rural patients
The global burden of COPD is high, and prevalence of nonsmokers with COPD has been increasing. In a study to be presented at CHEST Congress Thailand 2019, researchers in Nagpur, India, sought to describe the characteristics of nonsmoking patients with COPD and to determine associated comorbidities and exposures.
Researchers examined 180 nonsmoking patients with COPD between the years of 2016 and 2018. Each patient was categorized into either mild, moderate, severe and very severe COPD, based on their responses to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline questionnaires.
In this cohort, the percentage of mild, moderate, severe and very severe patients were 26%, 53%, 58% and 43%, respectively. The most common comorbidity among nonsmoker COPD was hypertension (34.4%) followed by diabetes mellitus (17.8%). Most of the patients (61%) lived in rural areas, while 38% belonged to urban areas. Forty six percent of patients had exposure to biomass gas, while 26% had exposure to toxic gases. These results support that exposure to biomass fuel is a major contributing factor to COPD and a higher risk among the rural population.
“Exposure to industrial smoke, environmental pollution and household smoke are major contributors for COPD in nonsmokers,” says Dr. Sameer Arbat, lead researcher. “There is a need to study this subset of nonsmokers having COPD further to determine the true cause of this increase.”
Further results from this study will be shared at CHEST Congress 2019 in Bangkok on Friday, April 12, at 3:00 p.m., in the Exhibition Hall. The study abstract can be viewed on the journal CHEST® website.
About CHEST Congress 2019 Thailand
CHEST Congress 2019 is a global event connecting clinicians from around the world specializing in pulmonary, critical care and sleep medicine, held April 10-12, 2019, in Bangkok, Thailand, with the support of the Thoracic Society of Thailand. The American College of Chest Physicians, publisher of the journal CHEST®, is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research and team-based care. Its mission is to champion the prevention, diagnosis and treatment of chest diseases through education, communication and research. It serves as an essential connection to clinical knowledge and resources for its 19,000 members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For more information about CHEST Congress 2019, visit chestcongress.chestnet.org, or follow CHEST meeting hashtag, #CHESTCongress19, on social media.
Related Journal Article